monday.com (NASDAQ:MNDY – Get Free Report) had its price target increased by analysts at Barclays from $300.00 to $325.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 20.24% from the stock’s current price.
Several other research analysts have also recently weighed in on the stock. DA Davidson boosted their price objective on shares of monday.com from $250.00 to $300.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 25th. Piper Sandler restated an “overweight” rating and issued a $300.00 price objective (up previously from $270.00) on shares of monday.com in a research report on Monday, August 12th. Bank of America boosted their price objective on shares of monday.com from $280.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. KeyCorp dropped their price objective on shares of monday.com from $280.00 to $270.00 and set an “overweight” rating for the company in a research report on Tuesday, July 2nd. Finally, Tigress Financial boosted their price objective on shares of monday.com from $280.00 to $340.00 and gave the stock a “buy” rating in a research report on Wednesday, August 21st. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $296.16.
Read Our Latest Report on MNDY
monday.com Price Performance
monday.com (NASDAQ:MNDY – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.01 by $0.23. The business had revenue of $236.11 million for the quarter, compared to the consensus estimate of $227.96 million. monday.com had a return on equity of 4.74% and a net margin of 4.88%. On average, equities analysts forecast that monday.com will post 0.49 EPS for the current year.
Hedge Funds Weigh In On monday.com
Several institutional investors and hedge funds have recently made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of monday.com in the 2nd quarter valued at $28,747,000. Sanctuary Advisors LLC acquired a new position in shares of monday.com in the 2nd quarter valued at $285,000. Truist Financial Corp grew its holdings in shares of monday.com by 4.1% in the 2nd quarter. Truist Financial Corp now owns 4,993 shares of the company’s stock valued at $1,202,000 after buying an additional 195 shares during the period. Mackenzie Financial Corp grew its holdings in shares of monday.com by 23.0% in the 2nd quarter. Mackenzie Financial Corp now owns 1,981 shares of the company’s stock valued at $477,000 after buying an additional 371 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of monday.com by 19.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,355 shares of the company’s stock valued at $2,975,000 after buying an additional 2,023 shares during the period. Institutional investors and hedge funds own 73.70% of the company’s stock.
About monday.com
monday.com Ltd., together with its subsidiaries, develops software applications in the United States, Europe, the Middle East, Africa, the United Kingdom, and internationally. The company provides Work OS, a cloud-based visual work operating system that consists of modular building blocks used and assembled to create software applications and work management tools.
Further Reading
- Five stocks we like better than monday.com
- Earnings Per Share Calculator: How to Calculate EPS
- Why Lennar Stock Could Be the Best Play in the Housing Market
- How to Invest in the FAANG Stocks
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Differences Between Momentum Investing and Long Term Investing
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for monday.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for monday.com and related companies with MarketBeat.com's FREE daily email newsletter.